Our latest investment in Scopio Labs Ltd., a pioneer in full-field digital cell morphology imaging and analysis, will pave the way for significant advancements in the future of hematology.
Historically, blood cell analysis has relied heavily on manual microscopy. Despite advances in hematology solutions, the field has seen limited innovation in the last few decades. Today, Scopio revolutionizes this landscape with its full-field cell morphology solution, automating and digitizing the blood cell analysis process.
Scopio’s advanced computational photography delivers sharp, 100X resolution images of entire blood samples. This provides lab practitioners with a full-field view of all regions of clinical interest on the sample at the highest resolution. By integrating this full-field technology with clinical AI-based decision support, Scopio enhances workflow efficiency, facilitates remote consultation, expedites decision-making, and improves patient care, all while reducing time and costs.
Scopio is experiencing a defining inflection point, supported by a highly skilled leadership team with extensive expertise in research and development. Their practical experience and strategic vision are crucial for driving advancements in digital cell morphology.
We are excited to partner with Scopio as they continue to revolutionize the hematology landscape. This funding will accelerate market penetration, expand global reach, and advance the development of Scopio’s digital morphology platform. It will also enhance sales and marketing efforts, strengthen customer support, and facilitate the creation of next-generation products to meet the evolving needs of laboratories and hospitals.
